These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 8923605)

  • 1. Occupational history and genetic N-acetyltransferase polymorphism in urothelial cancer patients of Leverkusen, Germany.
    Golka K; Prior V; Blaszkewicz M; Cascorbi I; Schöps W; Kierfeld G; Roots I; Bolt HM
    Scand J Work Environ Health; 1996 Oct; 22(5):332-8. PubMed ID: 8923605
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polymorphism of N-acetyltransferase 2 (NAT2) gene polymorphism in shanghai population: occupational and non-occupational bladder cancer patient groups.
    Ma QW; Lin GF; Chen JG; Xiang CQ; Guo WC; Golka K; Shen JH
    Biomed Environ Sci; 2004 Sep; 17(3):291-8. PubMed ID: 15602826
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The enhanced bladder cancer susceptibility of NAT2 slow acetylators towards aromatic amines: a review considering ethnic differences.
    Golka K; Prior V; Blaszkewicz M; Bolt HM
    Toxicol Lett; 2002 Mar; 128(1-3):229-41. PubMed ID: 11869833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NAT2 slow acetylation and bladder cancer in workers exposed to benzidine.
    Carreón T; Ruder AM; Schulte PA; Hayes RB; Rothman N; Waters M; Grant DJ; Boissy R; Bell DA; Kadlubar FF; Hemstreet GP; Yin S; LeMasters GK
    Int J Cancer; 2006 Jan; 118(1):161-8. PubMed ID: 16003747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. N-acetyltransferase-2 and medical history in bladder cancer cases with a suspected occupational disease (BK 1301) in Germany.
    Weistenhofer W; Blaszkewicz M; Bolt HM; Golka K
    J Toxicol Environ Health A; 2008; 71(13-14):906-10. PubMed ID: 18569594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Occupational and non-occupational risk factors in bladder cancer patients in an industrialized area located in former East-Germany].
    Golka K; Seidel T; Dietrich H; Roth G; Rötzel C; Thier R; Geller F; Reckwitz T; Schulze H
    Aktuelle Urol; 2005 Sep; 36(5):417-22. PubMed ID: 16163604
    [TBL] [Abstract][Full Text] [Related]  

  • 7. N-acetyltransferase 2 phenotype in painters with bladder cancer and controls.
    Golka K; Weistenhofer W; Jedrusik P; Geller F; Blaszkewicz M; Bolt HM
    Ann Acad Med Singap; 2001 Sep; 30(5):464-7. PubMed ID: 11603126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical relevance of acetylator phenotyping in 196 urothelial tumor patients].
    Schöps W; Prior V; Golka K; Blaszkewicz M; Cascorbi I; Roots I; Bolt HM; Kierfeld G
    Urologe A; 1997 Jan; 36(1):64-7. PubMed ID: 9123684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acetylation phenotypes and bladder cancer.
    Hanke J; Krajewska B
    J Occup Med; 1990 Sep; 32(9):917-8. PubMed ID: 2074519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glutathione S-transferase and N-acetyltransferase genotypes and asbestos-associated pulmonary disorders.
    Hirvonen A; Saarikoski ST; Linnainmaa K; Koskinen K; Husgafvel-Pursiainen K; Mattson K; Vainio H
    J Natl Cancer Inst; 1996 Dec; 88(24):1853-6. PubMed ID: 8961976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. N-Acetyltransferase 2 (NAT2) and Glutathione S-Transferase µ (GSTM1) in Bladder-cancer Patients in a Highly Industrialized Area.
    Golka K; Reckwitz T; Kempkes M; Cascorbi I; Blaskewicz M; Reich SE; Roots I; Soekeland J; Schulze H; Bolt HM
    Int J Occup Environ Health; 1997 Apr; 3(2):105-110. PubMed ID: 9891107
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Refinement of the prediction of N-acetyltransferase 2 (NAT2) phenotypes with respect to enzyme activity and urinary bladder cancer risk.
    Selinski S; Blaszkewicz M; Ickstadt K; Hengstler JG; Golka K
    Arch Toxicol; 2013 Dec; 87(12):2129-39. PubMed ID: 24221535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. N-acetyltransferase 2 phenotype, occupation, and bladder cancer risk: results from the EPIC cohort.
    Pesch B; Gawrych K; Rabstein S; Weiss T; Casjens S; Rihs HP; Ding H; Angerer J; Illig T; Klopp N; Bueno-de-Mesquita B; Ros MM; Kaaks R; Chang-Claude J; Roswall N; Tjønneland A; Overvad K; Clavel-Chapelon F; Boutron-Ruault MC; Dossus L; Boeing H; Weikert S; Trichopoulos D; Palli D; Sieri S; Tumino R; Panico S; Quirós JR; González C; Sánchez MJ; Dorronsoro M; Navarro C; Barricarte A; Ljungberg B; Johansson M; Ulmert D; Ehrnström R; Khaw KT; Wareham N; Key TJ; Ferrari P; Romieu I; Riboli E; Brüning T; Vineis P
    Cancer Epidemiol Biomarkers Prev; 2013 Nov; 22(11):2055-65. PubMed ID: 24092628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of interindividual variation in NAT2 activity on benzidine urinary metabolites and urothelial DNA adducts in exposed workers.
    Rothman N; Bhatnagar VK; Hayes RB; Zenser TV; Kashyap SK; Butler MA; Bell DA; Lakshmi V; Jaeger M; Kashyap R; Hirvonen A; Schulte PA; Dosemeci M; Hsu F; Parikh DJ; Davis BB; Talaska G
    Proc Natl Acad Sci U S A; 1996 May; 93(10):5084-9. PubMed ID: 8643532
    [TBL] [Abstract][Full Text] [Related]  

  • 15. N-acetylation phenotype and genotype and risk of bladder cancer in benzidine-exposed workers.
    Hayes RB; Bi W; Rothman N; Broly F; Caporaso N; Feng P; You X; Yin S; Woosley RL; Meyer UA
    Carcinogenesis; 1993 Apr; 14(4):675-8. PubMed ID: 8472331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. N-acetyltransferase 2 phenotype but not NAT1*10 genotype affects aminobiphenyl-hemoglobin adduct levels.
    Probst-Hensch NM; Bell DA; Watson MA; Skipper PL; Tannenbaum SR; Chan KK; Ross RK; Yu MC
    Cancer Epidemiol Biomarkers Prev; 2000 Jun; 9(6):619-23. PubMed ID: 10868698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The glutathione S-transferase M1 (GSTM1) null genotype and benzidine-associated bladder cancer, urine mutagenicity, and exfoliated urothelial cell DNA adducts.
    Rothman N; Hayes RB; Zenser TV; DeMarini DM; Bi W; Hirvonen A; Talaska G; Bhatnagar VK; Caporaso NE; Brooks LR; Lakshmi VM; Feng P; Kashyap SK; You X; Eischen BT; Kashyap R; Shelton ML; Hsu FF; Jaeger M; Parikh DJ; Davis BB; Yin S; Bell DA
    Cancer Epidemiol Biomarkers Prev; 1996 Dec; 5(12):979-83. PubMed ID: 8959320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Acetylation phenotype as a biomarker of sensitivity to the carcinogenic effect of aromatic amines].
    Indulski JA; Krajewska B; Lutz W
    Med Pr; 1992; 43(5):427-35. PubMed ID: 1293477
    [TBL] [Abstract][Full Text] [Related]  

  • 19. More on adducts and addicts. Slow N-acetylation genotype is a susceptibility factor in occupational and smoking related bladder cancer.
    Coggon D
    Hum Exp Toxicol; 1995 Jun; 14(6):538-9. PubMed ID: 8519531
    [No Abstract]   [Full Text] [Related]  

  • 20. [N-acetylation polymorphism versus differentiation of organic susceptibility to carcinogenic effect of homo- and heterocyclic aromatic amines].
    Lutz W; Barański B; Krajewska B
    Med Pr; 1994; 45(4):343-9. PubMed ID: 7968503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.